Ra Pharmaceuticals, Inc.
(NASDAQ : RARX)

( )
RARX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
-0.92%42.210.9%$1173.21m
JNJJohnson & Johnson
0.49%136.360.6%$1020.97m
MRKMerck & Co., Inc.
0.25%79.440.6%$955.62m
LLYEli Lilly and Company
0.45%122.681.0%$929.98m
BMYBristol-Myers Squibb Company
-0.12%51.301.4%$762.74m
ABBVAbbVie, Inc.
-0.66%79.992.2%$664.08m
AZNAstraZeneca PLC Sponsored ADR
0.20%40.541.3%$196.51m
NVSNovartis AG Sponsored ADR
0.89%90.770.2%$190.67m
GSKGlaxoSmithKline plc Sponsored ADR
0.17%41.360.2%$140.14m
NVONovo Nordisk A/S Sponsored ADR Class B
-1.24%49.700.1%$72.95m
SNYSanofi Sponsored ADR
-0.17%42.150.2%$37.62m
LCILannett Company, Inc.
2.57%9.8037.0%$16.93m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.09%1.871.7%$0.06m
EPIXESSA Pharma Inc
2.67%3.810.1%$0.05m

Company Profile

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The firm's lead product, RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.